<DOC>
	<DOC>NCT02484690</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of RG7716 in participants with subfoveal CNV secondary to AMD.</brief_summary>
	<brief_title>AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adults at least 50 years of age Subfoveal CNV lesions of all types, secondary to AMD Active CNV CNV due to causes other than AMD Subretinal hemorrhage, fibrosis, or atrophy involving either the fovea or more than 50% of the total lesion area Cataract surgery within 3 months of Baseline, or any other previous intraocular surgery Major illness or surgery within 1 month prior to Screening Hemoglobin A1c above 7.5 percent (%) Uncontrolled blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>